Vivos Therapeutics (VVOS) AI Stock Analysis

• Market Cap: $24.21M
• Dividend Yield: N/A
• Average Volume (3M): 360.91K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.85
• Revenue Growth: 9.47%
• EPS Growth: 81.37%
• Country: US
• Employees: 109
• Sector: Healthcare
• Sector Strength: 50
• Industry: Medical - Devices
• EPS (TTM): -0.55
• Shares Outstanding: 5,889,520
• 10 Day Avg. Volume: 128,415
• 30 Day Avg. Volume: 360,909
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: 0.85
• Enterprise Value/Revenue: 1.40
• Enterprise Value/Gross Profit: 2.39
• Enterprise Value/Ebitda: -1.95
• 1Y Price Target: $3.13
• Price Target Upside: -29.66% Downside
• Rating Consensus: Hold
• Number of Analyst Covering: 2

• Rating: 47 Neutral
• Price Target: $4.00 ▼(-10.11% Downside)

Vivos Therapeutics faces significant financial and technical challenges, with weak profitability and bearish momentum. However, strategic acquisitions and financing efforts provide potential for future growth.

Positive Factors

Cost Control

Operating expenses in Q4 FY24 were down 21% yoy to $4.9 million, reflecting the company’s ongoing focus on cost control.

Regulatory Approvals

FDA approves use of Vivos CARE appliances to treat moderate to severe OSA in children, a first in the industry.

Revenue Growth

Vivos's new selling model can result in 4-6 times as much revenue per case while accessing many more patients with healthy margins.

Negative Factors

Financing Concerns

The need for additional financing presents the likelihood of further dilutive financing in the next few quarters.

Operational Strategy

The company is transitioning its go-to-market strategy to direct alliances with sleep medicine specialists, aiming to expand its sleep testing partnership nationally.

Vivos Therapeutics Business Overview & Revenue Model

Company Description

Vivos Therapeutics, Inc. is a medical technology company specializing in the development and commercialization of treatments for obstructive sleep apnea (OSA) and related sleep disorders. The company leverages its proprietary Vivos System, which combines cutting-edge oral appliance technology with a multidisciplinary therapeutic protocol to address the underlying causes of OSA. Vivos operates within the healthcare sector, focusing primarily on dental and medical practices to deliver its innovative solutions.

How the Company Makes Money

Vivos Therapeutics generates revenue primarily through the sale of its Vivos System, which includes customized oral appliances and the associated therapeutic protocols. The company partners with dental and medical professionals, enrolling them into its Vivos Integrated Practice program, where practitioners are trained and certified to offer the Vivos System to patients. Revenue is also derived from the sale of appliances to these practitioners, who then provide them to patients as part of their treatment plans. Additionally, Vivos may earn from ongoing training, support services, and potential licensing agreements related to its technologies. The company's business model is bolstered by its strategic partnerships with healthcare providers and continuous efforts in research and development to enhance its product offerings.

Vivos Therapeutics Financial Statement Overview

Summary

Vivos Therapeutics shows positive revenue growth but struggles with profitability, indicated by negative EBIT and EBITDA margins. The balance sheet is improving with rising equity but high leverage remains a concern. Persistent negative free cash flow highlights ongoing cash burn, impacting financial stability.

Income Statement

Vivos Therapeutics has shown some positive revenue growth, with a 8.9% increase in 2024 compared to 2023. However, the company continues to face challenges in achieving profitability, indicated by negative EBIT and EBITDA margins, and a net income of zero in 2024. The consistent negative net profit margin over the years highlights ongoing operational struggles.

Balance Sheet

The balance sheet reflects improving equity, with stockholders' equity rising to $7.95 million in 2024 from $0.41 million in 2023, suggesting strengthened financial stability. However, the debt-to-equity ratio is relatively high, indicating potential leverage risks. The equity ratio remains moderate, demonstrating a balanced asset structure, but further stability is needed.

Cash Flow

The cash flow statement reveals persistent negative free cash flow, with minimal improvement over the years. Operating cash flow remains negative, highlighting ongoing cash burn, although financing activities have supported liquidity. The company needs to focus on improving operational efficiency to enhance cash flow stability.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	14.63M	15.03M	13.80M	16.02M	16.89M	13.07M
Gross Profit	8.59M	9.02M	8.27M	10.02M	12.60M	10.41M
EBITDA	-10.52M	-10.55M	-16.68M	-24.36M	-19.54M	-11.24M
Net Income	-11.24M	-11.14M	-13.58M	-22.66M	-20.29M	-8.82M
Balance Sheet
Total Assets	11.28M	15.28M	10.73M	13.72M	33.69M	25.33M
Cash, Cash Equivalents and Short-Term Investments	2.34M	6.26M	1.64M	3.52M	24.03M	18.21M
Total Debt	1.40M	1.51M	2.00M	2.41M	1.63M	1.29M
Total Liabilities	6.88M	7.33M	10.32M	8.92M	8.15M	8.41M
Stockholders Equity	4.41M	7.95M	411.00K	4.80M	25.54M	16.92M
Cash Flow
Free Cash Flow	-13.98M	-13.26M	-12.75M	-20.51M	-18.13M	-5.80M
Operating Cash Flow	-13.97M	-12.69M	-11.95M	-19.59M	-15.73M	-5.68M
Investing Cash Flow	-539.00K	-568.00K	-853.00K	-924.00K	-2.61M	-120.25K
Financing Cash Flow	14.24M	17.88M	10.92M	0.00	24.17M	23.54M

Vivos Therapeutics Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 4.45
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For VVOS, the sentiment is Negative. The current price of 4.45 is below the 20-day moving average (MA) of 4.70, above the 50-day MA of 4.35, and above the 200-day MA of 3.65, indicating a neutral trend. The MACD of -0.09 indicates Positive momentum. The RSI at 44.43 is Neutral, neither overbought nor oversold. The STOCH value of 43.63 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for VVOS.

Vivos Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
VVOS	47 Neutral	$24.21M	―	-450.47%	―	9.47%	81.37%
Sector *	47 Neutral	C$212.32M	0.03	-30.33%	3.13%	19.38%	-2.35%
PAVM	46 Neutral	$7.78M	0.37	-499.57%	―	-73.36%	―
CODX	45 Neutral	$12.33M	―	-63.40%	―	-91.14%	9.47%
ADGM	40 Underperform	$19.69M	―	-329.16%	―	15.00%	71.57%
AXDXQ	37 Underperform	$25.00	―		―	-2.99%	59.87%
BSGM	34 Underperform	$156.15M	―	5400.35%	―	-67.50%	45.54%

Vivos Therapeutics Corporate Events

Vivos Therapeutics Acquires The Sleep Center of Nevada

On June 10, 2025, Vivos Therapeutics completed the acquisition of The Sleep Center of Nevada, marking its first major acquisition of a sleep testing center. This strategic move is expected to enhance Vivos’ revenue through both diagnostic and consulting services, as well as sales of its patented OSA treatment appliances. The acquisition aligns with Vivos’ pivot to focus on high patient volume centers and higher margin revenues, supported by over $11 million in new financing, including a senior secured loan and a private placement investment. This acquisition provides Vivos direct access to a large patient base, potentially reducing cash burn and moving towards cash flow positivity.

Vivos Therapeutics Secures $1.1M Convertible Note

On May 21, 2025, Vivos Therapeutics, Inc. secured a convertible promissory note of $1,100,000 from V-Co Investors 2 LLC to support its acquisition of The Sleep Center of Nevada, expected to close by July 31, 2025. The note includes a $100,000 financing fee and provisions for conversion into equity upon a subsequent financing, with specific terms in case of default, highlighting strategic financial maneuvers to enhance its operational capabilities.